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1. Introduction 
Since the advent of flexible fiberoptic bronchoscopy (FFB) in the 1970’s, the use of sedation 
and topical anesthesia has allowed the practice of bronchoscopy, specifically FFB, to evolve 
from the operating room to the outpatient setting. Early techniques of general anesthesia 
and regional blockade of nerves innervating the airway have been largely replaced by 
improved techniques of patient monitoring, intravenous conscious sedation, and application 
of topical anesthetics in the airway. Today the bronchoscopist, in addition to basic FFB 
techniques such as bronchoalveolar lavage and transbronchial biopsy, can also perform 
complicated procedures such as removal of foreign bodies, ablation of airway tumors, and 
endobronchial stenting, all in the outpatient bronchoscopy suite. A continued emphasis has 
been placed on improvements in patient safety due to the complexities of the procedure 
itself, but also the role of conscious sedation and topical anesthetics to ensure maximal 
performance by the bronchoscopist to achieve the desired goal of successful biopsy or other 
interventions while the patient remains comfortable throughout the entire procedure. A full 
understanding of the patient’s medical history, underlying risk factors such as 
cardiovascular and pulmonary disease, and medication use is required to plan the 
requirements for the FFB. 
1.1 Guidelines for bronchoscopy 
There is some expert consensus guidance published on the use of sedation and topical 
anesthesia during FFB. The National Institutes of Health published a workshop summary on 
the investigational use of FFB in patients with asthma in 1985 (National Institutes of Health 
[NIH], 1985). Further recommendations for investigational FFB in asthmatics was provided 
in 1991 and commented on potential hazards, high risk and unsuitable patients, and 
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procedural limitations (NIH, 1991). The American Thoracic Society (ATS) published a 
concise one-page guideline in 1987 which outlined diagnostic and therapeutic uses, research 
applications, conditions with increased risk, and contraindications for FFB (American 
Thoracic Society [ATS], 1987). It did not, however, provide any specific guidance on the 
optimal use of topical anesthesia or intravenous sedation. In 2001, the British Thoracic 
Society published a more complete guideline and made several major recommendations 
related to sedation and topical anesthesia for all patients undergoing FFB (British Thoracic 
Society [BTS], 2001). All of the following recommendations had level B evidence (except for 
#8 with level C) to support their use. 
1. Sedation should be offered to patients where there is no contraindication. 
2. Atropine is not required routinely before bronchoscopy. 
3. Patients should be monitored by pulse oximetry. 
4. Oxygen supplementation should be used to achieve an oxygen saturation of at least 
90% to reduce the risk of significant arrhythmias during the procedure and also in the 
postoperative recovery period. 
5. The total dose of lidocaine should be limited to 8.2 mg/kg in adults (approximately 29 
ml of a 2% solution for a 70 kg patient) with extra care in the elderly or those with liver 
or cardiac impairment. 
6. The minimum amount of lidocaine necessary should be used when instilled through 
the bronchoscope. 
7. Sedatives should be used in incremental doses to achieve adequate sedation and 
amnesia. 
8. Routine ECG monitoring during bronchoscopy is not required but should be 
considered in those patients with a history of severe cardiac disease and those who 
have hypoxia despite oxygen supplementation. 
A survey of BTS pulmonologists was conducted after the publication of these guidelines 
(Pickles et al., 2003). A variety of lidocaine (or lignocaine) preparations to include gel, spray, 
and nebulized were used in 97% of patients with rare use of other anesthetics such as 
cocaine or amethocaine lozenges. Interestingly, sedation was most commonly done with 
midazolam but was not used by 27% of respondents citing age, frailty, and medical co-
morbidities. Assessment of sedation during FFB was most frequently done by 
measurements of oxygen saturations (98%) and observation of patient response (57%). 
Similar findings on the lack of standardization were noted in a separate survey of BTS 
pulmonologists (Smyth et al., 2002). 
1.2 Contraindications 
The American Thoracic Society (ATS) 1987 guidelines presented four absolute 
contraindications to the performance of FFB that included: 1) operator inexperience, 2) lack 
of adequate facilities, 3) absence of informed consent, and 4) inability to maintain adequate 
oxygenation. Other significant contraindications thought to confer a high risk to patients 
during FFB included: 1) profound refractory hypoxemia; 2) severe bleeding diathesis 
uncorrectable prior to the procedure, and 3) malignant cardiac arrhythmias (ATS, 1987). 
Other medical conditions that also increased the risk of FFB and were listed as relative 
contraindications included: 1) lack of patient cooperation, 2) recent myocardial infarction or 
unstable angina, 3) respiratory insufficiency or failure, 4) uremia, 5) unstable asthma, 6) 
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unstable cardiac arrhythmias, and 7) significant debilitation or malnutrition. The 2001 BTS 
guidelines do not present any specified contraindications but noted there are no controlled 
studies of the patient risk factors and each patient must be individually assessed based on 
the risk-benefit ratio (BTS, 2001). 
2. Preparation for bronchoscopy 
The goal of patient assessment for any invasive procedure such as FFB is to forewarn of 
potential complications or to identify complications that occur as a result of the procedure. 
Possible bronchoscopic complications may include a variety of respiratory, cardiac, and 
other conditions (Pereira et al., 1978, Suratt et al., 1976). Reported respiratory complications 
include hypoxia, hypercapnea, laryngospasm, bronchospasm, pulmonary edema, 
aspiration, airway obstruction, pneumomediastinum and pneumothorax (Facciolongo et al., 
2009). Cardiac complications can include vasovagal reactions, tachycardia, bradycardia, 
dysrhythmias, and myocardial infarction. Other reported complications are airway trauma, 
hemorrhage, epistaxis, infection, nausea and vomiting, adverse reactions to topical 
anesthesia, exposure to radiation, and death. In an attempt to avoid these possible events, 
preparation of the patient begins with the initial assessment and evaluation, and monitoring 
continues through all phases of FFB. 
2.1 Patient evaluation 
All patients with an indication for FFB should undergo a historical assessment to identify 
potential bleeding, respiratory, medication, neurologic, or cardiovascular risks. These could 
potentially include blood dyscrasias, uremia, anti-coagulant or anti-platelet medications, 
surgical or dental history, a history of asthma, cervical spine disease, interstitial pneumonia, 
upper airway obstructions, congenital defects, cardiac history, epilepsy, neoplastic mass or 
therapies. A previous history of bronchoscopy complications, adverse reactions to sedation, 
drug or alcohol abuse history may also prove useful (American Society of Anesthesiologists 
[ASA], 2002). Additionally, a family history for clotting complications or bleeding disorders 
may suggest when a patient is at higher risk for complication. The airway exam should 
include an assessment of potential bronchoscope entry points in either nares or mouth for 
potential risks such as small lumens, excessive deviation, congenital deformities or loose 
dentition. As some patients require intubation due to procedural complications a 
Mallampati score, exam of habitus, neck, jaw, and oral structures as they affect direct 
laryngoscopic intubation are also recommended. Pulmonary exams should include an 
assessment for tachypnea, increased effort or asymmetry, “barrel-chest”, auscultation, 
cyanosis or clubbing. As bleeding and cardiovascular events have also been reported to 
complicate bronchoscopy a focused exam to identify potential risk factors in these systems 
should also be performed. Finally, an American Society of Anesthesiologist’s Physical Status 
Classification should also be recorded (ASA, 2002). 
All patients undergoing FFB with sedation should undergo a thorough evaluation to include 
medical and surgical history, current medications, drug allergies, and amount and type of 
alcohol and illicit drug use. Medical and surgical history should focus on evaluating the 
patient’s degree of cardiac and respiratory compromise and reserve physiology. Close 
attention and consideration should be given to those with obstructive lung disease, obstructive 
sleep apnea, neuromuscular disorders, renal and hepatic impairments. Physical exam should 
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focus on upper airway abnormalities, assessment of potential difficult airway anatomy, 
pulmonary system focusing on active airway obstruction, and gross neurologic function.  
2.2 Pulmonary function testing 
Pulmonary function testing should be performed if there is clinical suspicion for severe 
obstruction. The BTS guideline suggests testing be performed when forced expiratory 
volume at one second (FEV1) is less than 40% predicted or oxygen saturation (SaO2) is less 
than 93% (BTS, 2001). One small prospective trial reported a drop of 13.8% in FEV1 (baseline 
1.37 ± 0.16L) approximately 15 minutes into bronchoscopy (Salisbury et al., 1975). A slightly 
larger retrospective review reported patients who had a FEV1/forced expiratory volume 
(FVC) ratio less than 50% or an FEV1 less than one liter with an FEV1/FVC ratio less than 
69% had a bronchoscopic complication rate of 5% compared to 0.6% of controls with normal 
spirometric function (Peacock et al., 1994). If the patient requires additional procedures such 
as bronchoalveolar lavage or transbronchial biopsy and there are concerns for possible 
respiratory compromise, screening spirometry may also be useful. Lima reported that 
patients with diffuse lung disease have a decrease of approximately 12.7% in FEV1 following 
bronchoalveolar lavage (Lima et al., 2009). 
2.3 Radiographic studies 
It is assumed that a patient who is scheduled to undergo FFB has already had a chest 
radiograph performed given the minimal risk and ability to non-invasively assess the 
thorax. However, if a computed tomography (CT) scan of the chest has not already been 
performed, it should be considered for patients with hemoptysis or undergoing a neoplastic 
evaluation. A higher diagnostic sampling yield for malignancy has been reported if the 
patient had a CT performed prior to bronchoscopy (Bungay et al., 2000; Laroche et al., 2000). 
Additionally, in cases of hemoptysis, pre-procedural CT was able to improve sampling in 
patients who were at higher risk for neoplastic associated hemoptysis, obviate the need for 
invasive evaluation, or help identify areas of bronchiectasis for sampling (McGuinness et al., 
1994; Tsoumakidou et al., 2006). 
2.4 Laboratory testing 
A large number of practitioners empirically order coagulation tests prior to performing FFB. 
The ability of these tests to predict bleeding risks prior to FFB is controversial and several 
sources recommend against routine testing (Bjørtuft et al., 1998; Kozak & Brath, 1994; Segal 
et al., 2005). Additionally, Weiss reported bleeding risks in a group of thrombocytopenic 
patients with platelet counts less than 100,000 who underwent a total of 58 FFB procedures. 
There were seven occurrences of epistaxis and/or hemorrhage but only one patient 
experienced severe epistaxis despite an oral approach and a platelet count of 18,000 (Weiss 
et al., 1993). Thus, routine testing without significant suspicion for bleeding risk is not 
recommended. A pre-procedural arterial blood gas is recommended in the 2001 BTS 
guidelines for the same patients who may benefit from a pre-procedural PFT, FEV1 less than 
40% predicted or SaO2 <93% (BTS, 2001). There is scant available data to support this 
recommendation except for the report by Salisbury in which one patient whose PaO2 
plummeted from 60 mm Hg to 38 mm Hg intra-procedurally and resolved with removal of 
the bronchoscope (Salisbury et al., 1975). 
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2.5 Anti-platelet medications and anticoagulants 
Anti-platelet agents and non-steroidal anti-inflammatory (NSAID) medications are 
commonly used by patients who have an indication for FFB. While there is a potential for 
bleeding complications from biopsy, there are few reported cases of complications related to 
NSAID medication use. Aspirin is not reported to increase the rate of bleeding 
bronchoscopic complications when compared to controls (Herth et al., 2002). However, the 
continued use of clopidogrel prior to bronchoscopy has been associated with a bleeding rate 
of 89% and up to 100% of patients who continued to take both aspirin and clopidogrel 
together (Ernst et al., 2006). In patients who can tolerate the cessation of antiplatelet therapy, 
the 2008 American College of Chest Physicians (ACCP) clinical practice guidelines 
recommend stopping clopidogrel seven to ten days before FFB while Ernst, et al. 
recommended stopping five to seven days before FFB.(Douketis et al., 2008; Ernst et al., 
2006) While the ACCP additionally recommends that NSAID medications be stopped five 
half-lives prior to a planned procedure with bleeding risk, there is no specific data on FFB to 
support this statement. Direct thrombin inhibitors and vitamin K antagonists such as 
warfarin are also commonly used by patients who require bronchoscopy. The 2008 ACCP 
Clinical Practice guidelines recommend cessation of warfarin for at least five days prior to a 
procedure with an INR assessment 1-2 days before the procedure for an INR < 1.5. Certain 
patients, i.e. those with mechanical valves, may also require bridging on other 
anticoagulants (Douketis et al., 2008).  
3. Monitoring during bronchoscopy 
3.1 Pre-procedure assessment 
Immediately prior to FFB, the patient should be re-evaluated for recent medical events or 
other changes in condition such as infection or flare of respiratory disease (ASA, 2002; BTS, 
2001). Patients who have experienced a recent myocardial infarction are recommended to 
have the procedure delayed for up to 6 weeks (BTS, 2001). The patient history of oral intake 
should be confirmed. In healthy patients without modifiers such as delayed gastric 
emptying, the ASA Pre-Procedure Fasting Guidelines recommend fasting for two hours for 
clear liquids, four hours for breast milk, and six hours for formula or light meals to decrease 
the risk of aspiration (ASA, 2002) The BTS guidelines for FFB lower the time limit for light 
meals to four hours (BTS, 2001). In all patients, intravenous access should be obtained and 
maintained throughout the procedure. Routine vital signs to confirm systemic and 
hemodynamic stability are recommended. If the patient has a high risk for cardiovascular 
disease, consideration should be given to obtain a 12-lead electrocardiogram (Shrader & 
Lakshminarayan, 1978). 
3.2 Intraprocedural monitoring 
For patients who will receive a moderate level of sedation (able to maintain spontaneous 
ventilation and respond to verbal or tactile stimuli), continuous hemodynamic monitoring 
should be used at five minute intervals (ASA, 2002). While it is uncertain that all patients 
undergoing FFB would benefit from intra-procedural continuous electrocardiographic 
monitoring, both societies recommend continued monitoring in patients who are at high 
cardiovascular risk. (ASA, 2002; BTS, 2001) A study of continuous electrocardiographic 
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monitoring demonstrated evidence of myocardial ischemia in 17% of 29 patients above the 
age of 50 undergoing FFB (Matot et al., 1997). 
3.3 Supplemental oxygen 
The routine use of supplemental oxygen during FFB has previously been a point of 
disagreement with some authors. Given the known risks for cardiac arrhythmia during 
periods of hypoxia, both supplemental oxygen administration and monitoring with pulse 
oximetry are recommended for all patients. The sensitivity of pulse oximetry to detect 
hypoxia compared to clinical exam should make this a routine part of FFB even in healthy or 
research patients, especially with the use of conscious sedation (ASA, 2002; BTS, 2001; 
Shrader & Lakshminarayan, 1978). Ghio et al. demonstrated evidence of hypoxia in healthy 
volunteers during the initiation of bronchoalveolar lavage (Ghio et al., 2007). Nearly 25% of 
patients in a study of 1,051 FFB required the use of supplemental oxygen for desaturations 
(Jones & O’Driscoll, 2000). The BTS recommends using supplemental oxygen to maintain a 
goal of SaO2 greater than 89% during and after FFB (BTS, 2001). Patients who undergo FFB 
are frequently at increased risk for hypercapnea due to intravenous sedation or underlying 
lung disease (Salisbury et al., 1975). While capnography is also more sensitive to 
hypercapnea than physical exam, there is no clear recommendation or evidence to support 
the routine use of capnography during FFB with moderate levels of sedation. 
3.4 Post-procedure assessment 
After FFB is completed, patients should continue to receive oximetry and be monitored until 
they are near their baseline state of consciousness and interaction (ASA, 2002). 
Supplemental oxygen should also be continued until the patient can spontaneously 
maintain a SaO2 greater than 89%. The return of the gag reflex and the ability to safely 
swallow clear liquids should be confirmed (BTS, 2001). If the patient has received 
transbronchial biopsies with or without fluoroscopic guidance, a chest radiograph should be 
performed one hour following the procedure (BTS, 2001). Transthoracic ultrasound has 
recently come to prominence for the ability to identify the presence of pneumothorax, but its 
routine use following FFB is not yet well established. 
4. Sedation 
Persons undergoing FFB can experience significant degree of anxiety, sense of asphyxiation, 
and severe coughing. Sedative and analgesic agents are frequently administered to patients 
undergoing bronchoscopy to reduce these noxious sensations. Both the ATS and the BTS 
guidelines recommend the use of sedation during bronchoscopy (ATS, 1987; BTS, 2001). 
Despite this, debate has continued regarding the necessity of sedation during FFB. Surveys 
have revealed increased physician comfort and use of sedation during bronchoscopy 
(McLean et al., 1998; Prakash et al., 1991). Patient satisfaction and willingness to pursue 
repeat FFB procedures if required has been shown to be higher in those receiving sedative 
and systemic analgesic agents (Gonzales et al., 2003; Hirose et al., 2008; Putinati et al., 1999; 
Steinfort & Irvin, 2010). Tolerance to FFB was clearly decreased in a prospective study of 357 
patients who received no sedation for their procedure (Lopez et al., 2006). Putinati et al. also 
demonstrated improved procedural success in those receiving sedative agents. 
Bronchoscopy was aborted prior to completion in six of fifty patients in the placebo group 
www.intechopen.com
 
Monitoring, Sedation, and Anesthesia for Flexible Fiberoptic Bronchoscopy 41 
(Putinati et al., 1999). Interestingly, Hatton et al. described decreased patient satisfaction and 
willingness to undergo repeat procedure when comparing midazolam to placebo (Hatton et 
al., 1994). Subsequent editorial comments highlight the difficulty in evaluating these studies 
as the results were criticized for insufficient medication dosing and administration sequence 
(Hanley, 1995).  
Previous reviews reveal wide variation in the practice patterns for sedation use during FFB 
(Matot & Kramer, 2000; Vincent & Silvestri, 2007). No single regimen has been found to be 
superior and previous guidelines did not have recommended regimens (BTS, 2001). 
Recently, the American College of Chest Physicians released a consensus statement on 
topical anesthesia, analgesia and sedation during FFB. The consensus statement suggested 
the use of lidocaine for topical anesthesia and the combination of a benzodiazepine and 
opiate administration for sedation and analgesia during the procedure, with propofol as an 
effective alternative agent (Wahidi et al., 2011). Multiple factors must be taken into 
consideration when selecting an analgesic and sedative regimen. Patient characteristics 
include age, co-morbidities, and baseline respiratory physiology. The procedure complexity 
and time required must be considered as an airway survey and bronchoalveolar lavage 
invariably requires less time and sedation than more complex procedures such as 
transbronchial biopsies, mediastinal lymph node sampling, debulking and stenting of 
endobronchial lesions. The degree of sedation required can vary greatly from mild sedation 
to general anesthesia (ASA, 2002). Increasingly complex FFB procedures are being 
performed without the assistance of general anesthesia including mediastinal lymph node 
staging with endobronchial ultrasound guidance with good patient satisfaction (Steinfort & 
Irvin, 2010). Finally one must be familiar with the degree of support staff able to provide pre 
and post-procedural care and monitoring during the recovery process. 
4.1 Degree of sedation 
The desired degree of sedation and analgesia should be determined for individual patients 
and follow American Society of Anesthesiologists (ASA) definitions: 
1. Minimal Sedation (Anxiolysis): A drug induced state with normal response to verbal 
stimulation with unaffected airway, spontaneous ventilation and cardiovascular 
function 
2. Moderate Sedation/Analgesia (Conscious Sedation): A drug induced state with 
purposeful response to verbal or tactile stimulation, no airway interventions required, 
maintains adequate spontaneous ventilation, and cardiovascular function typically 
maintained. 
3. Deep Sedation/Analgesia: A drug induced state with purposeful response after 
repeated or painful stimuli, airway intervention may be required, spontaneous 
ventilation may be inadequate and cardiovascular function typically maintained. 
4. General Anesthesia: A drug induced state in which patients are not arousable even with 
painful stimulus, airway intervention required, spontaneous ventilation frequently 
inadequate, and cardiovascular function may be impaired.  
The level of sedation required for FFB is typically minimal to moderate depending upon the 
type of procedure planned and is often performed by a non-anesthesiologist. When greater 
than moderate sedation is desired, those patients with limited cardiovascular or pulmonary 
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reserve, or prolonged procedure anticipated, it is recommended the expertise of an 
anesthesiologist be obtained.  
4.2 Sedative and analgesic agents 
Favorable agent profiles include relatively rapid onset of action, rapid and predictable 
recovery, with minimal hemodynamic instability and lack of significant respiratory 
depression at doses achieving desired level of sedation. For these reasons benzodiazepines, 
opioids, and more recently propofol have been increasingly used for sedation during FFB 
(Vincent & Silvestri, 2007). Other intravenous agents to improve patient comfort such as 
atropine are not currently recommended and limited studies have failed to demonstrate a 
significant benefit (Hasanoglu et al., 2001; Korteweg et al., 2004; Triller et al., 2004) 
4.2.1 Benzodiazepines 
Benzodiazepines have sedative-hypnotic, anxiolytic, and amnestic effects by interacting on 
GABA receptors. Frequently used agents include diazepam, midazolam, lorazepam, and 
temazepam (Greig et al., 1995; Leite et al., 2008; Vincent & Silvestri, 2007; Watts et al., 2005). 
Oral use of temazepam and diazepam has been described and appear to offer an 
appropriate degree of mild sedation/anxiolysis (Matot & Kramer, 2000; Watts et al., 2005). 
The advent of midazolam, a water soluble, short-acting benzodiazepine able to be given 
intravenously has made it the primary agent in many bronchoscopy suites. The metabolites 
of midazolam have minimal subsequent effects. Midazolam can be given via intermittent 
intravenous doses and tailored to patient responses. Caution should be used when 
administrating to the elderly and those with obstructive airway physiology. Sedation is 
typically effective for 20-40 minutes. Midazolam can be safely given in 0.5mg to 1mg 
increments at five minute intervals until desired level of sedation achieved. Another 
desirable attribute to benzodiazepines is the availability of a reversal agent. The competitive 
antagonist, flumazenil can rapidly reverse the effects of benzodiazepines. Though not 
standard practice, a study of 22 patients demonstrated successful reversal FB sedation using 
flumazenil (Williamson et al., 1997). Flumazenil use is typically reserved for benzodiazepine 
reversal in those patients experiencing sedation related hypoxia, need for improved airway 
clearance, or increasing hypercarbia. Flumazenil use should be avoided in those patients on 
chronic benzodiazepines due to possible seizure provocation.  
4.2.2 Opiates 
Opiates have both sedative and analgesic properties as well as antitussive effects. 
Frequently used opiate agents include fentanyl, alfentanil, remifentanil, meperidine and less 
frequently morphine. Many studies have evaluated opiate agents in combination with other 
sedatives including benzodiazepines and propofol (Greig et al., 1995; Hwang et al., 2005; 
Leite et al., 2008; Matot & Kramer, 2000; Vincent & Silvestri, 2007; Yoon et al., 2011). Greig et 
al. demonstrated that a lone opiate agent in combination with a benzodiazepine resulted in a 
reduced number of coughs and reduced topical lidocaine dose (Greig et al., 1995). Fentanyl 
and related agents are desired due to rapid onset of action, high potency, and short duration 
of action. A study of alfentanil with standard dose topical lidocaine revealed improved 
composite score of sedative effects and adverse events when compared to lidocaine alone or 
midazolam combined with topical lidocaine. The propofol combination composite score was 
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slightly superior to alfentanil combination (Leite et al., 2008). All opiates can produce 
respiratory depression and this is amplified when given in combination with another 
sedative agent (Yoon et al., 2011). If severe respiratory depression occurs, reversal of opiate 
agents can be obtained with naloxone use. Due to potential adverse hemodynamic effects of 
naloxone and sudden opiate reversal, this should be reserved for those patients with 
clinically significant respiratory depression.  
4.2.3 Propofol 
Propofol is an alkyl-phenol sedative-hypnotic agent in a lipid emulsion capable of 
producing a dose-dependent degree of sedation from conscious sedation to general 
anesthesia. It has a rapid onset of action (less than two minutes) and rapid recovery (less 
than 15 minutes) (Matot & Kramer, 2000; Vincent & Silvestri, 2007). When compared to 
alfentanil and midazolam as well as topical lidocaine, propofol had the lowest composite 
score indicating the lowest complication index (Leite et al., 2008). Propofol has been 
demonstrated to have improved patient neuropsychometric recovery with no difference in 
physician procedural sedation satisfaction when compared to midazolam (Clark et al., 2009). 
Propofol has also been reported to be a safe option for sedation in pediatric patients 
(Berkenbosch et al., 2004; Larsen et al., 2009). In a retrospective study, it must be noted 
however that fifty percent of pediatric patients were classified as having minor 
complications which included the need for supplemental oxygen, oropharyngeal suctioning 
or jaw-thrust to improve oxygen saturation (Larsen et al., 2009). Propofol in separate 
combinations with alfentanil and ketamine has been demonstrated to provide patient 
controlled sedation via a patient-controlled-analgesia device (Hwang et al., 2005). 
Fospropofol, a water-soluble prodrug of propofol, has been demonstrated to be a safe agent 
during FFB in a phase three trial (Silvestri et al., 2009). Mild to moderate hypoxia was noted 
in 15% of the patients given the described optimal sedative dose. One must be aware of and 
recognize the typically dose dependent hemodynamic effects (hypotension, decreased 
cardiac output) as well as the rare development of propofol infusion syndrome. 
5. Topical anesthesia 
Along with sedation, topical airway anesthesia is an important component of FFB as it 
provides the patient additional comfort and tolerability that sedation alone will not provide. 
Local anesthesia of the nares, oropharynx, and hypopharynx allows comfortable passage of 
the bronchoscope to the upper airway. More importantly, topical anesthesia of the airways 
beyond the glottis blunts the cough reflex and allows the bronchoscopist to visualize the 
airways and perform necessary procedures. Selected patients such as healthy volunteers 
with adequate topical anesthesia can tolerate FFB without the need for intravenous sedation 
(Ghio et al., 1998). There have been a variety of studies that have explored issues of patient 
comfort, tolerability of FFB and dosing regimens. While patient comfort is the primary goal, 
the ability for the bronchoscopist to complete the procedure is likewise paramount.  
5.1 Administration 
There is significant variation in the administration of topical anesthesia during FFB. The 
optimal preparation largely depends on the patient, the experience of the technician, and the 
estimated length of the procedure. A typical airway preparation for FFB in our institution 
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includes the application of 2% viscous lidocaine for the nasal mucosa, nebulized 4% topical 
lidocaine for oral inhalation prior to the FFB, and application of 1% topical lidocaine during 
the procedure for additional upper and lower airway mucosal anesthesia to control 
coughing. This airway preparation uses approximately 500 mg of topical lidocaine. The 
amount of 1% lidocaine used is highly variable and physician dependent with 
approximately 100 mg used for direct application to the vocal cords and carina and 
additional lidocaine used for lower airway anesthesia to suppress coughing. There are 
relatively few studies examining the optimal lidocaine dosing for patient comfort and safety 
during FFB. A study examining various lidocaine amounts (mg/kg) and strengths ranging 
from 1% to 2% in 96 patients found no differences between the six groups in terms of patient 
comfort (Mainland et al., 2001). The author recommended use of 1% lidocaine for topical 
airway anesthesia based on similar amounts of supplemental lidocaine doses and serum 
lidocaine levels. An earlier 1985 study demonstrated there was no effect on patient comfort 
scores when a fixed dose of 370 mg of lidocaine was compared with higher lidocaine doses 
with as needed dosing (mean lidocaine dose=512 mg) (Sutherland et al., 1985). Notably, the 
airway preparation in the fixed dose group used 1% lidocaine versus 2% in the uncontrolled 
group. A 2008 prospective study evaluating the equivalence of 1% versus 2% topical 
lidocaine during FFB demonstrated no difference in cough frequency or as needed doses of 
lidocaine by the bronchoscopist. The 2% lidocaine group received twice the mg/kg dose as 
the 1% lidocaine without increasing patient comfort (Hasmoni et al., 2008). Finally, the use 
of nebulized lidocaine during the FFB preparation is equivocal (Keane & McNicholas, 1992). 
Several studies have demonstrated less cough and safety when comparing nebulized 
lidocaine with other preparations (Gove et al., 1985; Graham et al., 1992) However, other 
studies were unable to demonstrate a benefit for nebulized lidocaine compared with saline 
placebo in terms of cough perception, patient discomfort, or use of supplemental lidocaine 
doses (Charalampidou et al., 2006; Stolz et al., 2005).  
5.2 Agents 
Lidocaine (or lignocaine) is the most commonly used topical anesthetic applied to the 
airway mucosa during FFB. Other agents that may be used include tetracaine (2%), 
benzocaine (10-20%), and cocaine (4-10%). Lidocaine is preferred as it is less toxic, more 
widely available to the bronchoscopist, and shorter acting than cocaine or tetracaine. 
Lidocaine is metabolized by the liver and may have side effects at serum levels greater than 
5 microgram/ml. Benzocaine has duration of action of only five to ten minutes and is not 
ideal for FFB; its use is limited by potential toxicity due to methemoglobinemia. Tetracaine 
has a longer duration of action but a very narrow margin of safety and is not advocated for 
use in FFB. Use of cocaine is limited due to excess sympathetic nervous system activity and 
possible toxicity and potential for abuse. However, direct comparisons of lidocaine with 
other preparations such as cocaine have shown equivalence in terms of patient tolerance 
(Teale et al., 1990) 
5.3 Dosing of topical anesthesia 
Initial guidelines for lidocaine dosing published by the National Institutes of Health (NIH) 
in 1985 recommended no more than 400 mg cumulative dose of lidocaine for healthy 
asthmatics undergoing FFB. This recommendation was primarily based on expert opinion 
(NIH, 1985). The updated 1991 NIH guidelines for FFB in asthmatics simply stated the 
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lowest topical anesthetic dose possible should be used (NIH, 1991). When the BTS published 
general guidelines for topical anesthesia in the routine clinical practice of FFB, their 
recommendation was based primarily on two recently published studies (BTS, 2001). A 
study of 48 asthmatics undergoing research FFB demonstrated safety with a mean dose of 
8.2 mg/kg of lidocaine as the upper limit of normal (Langmack et al., 2000). Another smaller 
study by Milman et al. of 16 patients undergoing FFB recommended a maximum dosage of 
6-7 mg/kg (Milman et al., 1998).  
The current medical literature contains a substantial collection of studies evaluating serum 
lidocaine levels during FFB. These studies evaluating lidocaine dosing have been done to 
evaluate a variety of techniques in application of topical anesthesia (Ameer et al., 1989; 
Amitai et al., 1990, Berger et al., 1989; Boye & Bresden, 1979; Efthimiou et al., 1982; Gjonaj et 
al., 1997; Gomez et al., 1983; Jones et al., 1982; Karvonen et al., 1976; Korttila et al., 1981; 
Langmack et al., 2000; Le Lorier et al., 1979; Loukides et al., 2000; Mainland et al., 2001; 
McBurney et al., 1984; Milman et al., 1998; Patterson et al., 1975; Smith et al., 1985; Sucena et 
al., 2004; Sutherland et al., 1985). These twenty studies were reviewed by Frey et al. in their 
study of lidocaine dosing (Frey et al., 2008). This compilation of studies included a total of 
457 patients whose mean age was 47.4 ± 23.7 years and the mean total dose of lidocaine was 
488 ± 463 mg. The mean lidocaine dose (reported as adjusted for weight) was 9.7 ± 5.0 
mg/kg. Only six of these studies gave a lidocaine dose greater than 8.2 mg/kg or total dose 
greater than 600 mg. None of the studies reported an average peak lidocaine level > 5.0 
mg/kg, while only three of the 21 studies reported a maximum lidocaine level > 5.0 mg/kg. 
This cumulative data of nearly 500 patients did not suggest a trend towards lidocaine 
toxicity despite higher lidocaine levels than the BTS recommendations (Frey et al., 2008) The 
Frey study collected measured lidocaine dosing and serum levels for 154 patients with a 
mean age of 64.7 years undergoing FFB. Mean lidocaine usage was 15.4 ± 4.5 mg/kg 
(1.17±0.20 gm), mean serum lidocaine level was 1.6 ± 0.7 mg/mL, and mean blood 
methemoglobin level was 0.7 ± 0.3%. No clinical toxicity was noted and the authors 
adequately demonstrated the safety of higher doses of topical lidocaine (Frey et al., 2008). 
Other studies have also demonstrated the safety of higher doses of lidocaine during FFB 
(Ameer et al., 1989; Gjonaj et al., 1997; Sucena et al., 2004]. In the earliest study in 1979, 12 
FOB patients received an average of 600 mg of topical lidocaine. The maximum lidocaine 
level was found to be 3.79 μg/ml in a patient with hepatic metastases who only received 420 
mg topical lidocaine (LeLorier et al., 1979). A follow-up study in 1982 by Efthimiou et al. of 
41 FOB patients used a similar mean lidocaine dose (9.3 ± 0.5 mg/kg); mean peak levels 
were 2.9 ± 0.5 μg/ml and two patients had a lidocaine level > 5 μg/ml with no 
complications (Efthimiou et al., 1982). Ameer et al. compared an elderly group of 14 patients 
(mean age of 67 years) with a young group of five patients (mean age of 42 years). Both 
groups received total lidocaine doses of nearly 1200 mg without significant toxicity. No 
difference in mean or peak serum lidocaine was found between groups (Ameer et al., 1989). 
As part of a study evaluating the effect of lidocaine on endobronchial cultures, Berger et al. 
studied eight patients who received an average total lidocaine dose greater than 2000 mg. 
The mean serum level was 2.7 μg/ml and the peak level in one patient was 5.5 μg/ml; no 
toxicity was reported (Berger et al., 1989). In 1997, Gjonaj et al. evaluated 8 mg/kg vs. 4 
mg/kg of nebulized 2% lidocaine in a pediatric population and found no evidence of 
toxicity. The total lidocaine dose for the high-dose group was 10.13 ± 1.26 mg/kg with mean 
serum lidocaine levels of 1.17 ± 0.54 μg/ml and peak levels of 2.27 μg/ml [Gjonaj et al., 
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1997). The most recent studies by Loukides (mean lidocaine dose of 622 ± 20 mg) and Sucena 
(mean lidocaine dose of 11.6 ± 3.1 mg/kg) also found no toxicities with these doses 
(Loukides et al., 2000; Sucena et al., 2004). Notably, five of 30 patients studied by Sucena et 
al. had serum levels greater than 5 μg/ml but no clinical toxicity (Sucena et al., 2004). 
5.4 Complications 
Serious effects of lidocaine toxicity (seizures, methemoglobinemia, respiratory failure, and 
cardiac arrhythmias) are reported to begin at serum levels > 5 μg/ml (Fahimi et al., 2007; 
Rodins et al., 2003; Sutherland et al., 1985; Wu et al., 1993). At lower serum concentrations, 
milder side effects such as drowsiness, dizziness, euphoria, paresthesias, nausea, and 
vomiting may occur. Consideration should also be given to allergic reactions due to 
lidocaine administration (Bose & Colt, 2008). Serum lidocaine clearance can be decreased in 
the elderly, patients with cardiac or liver disease, and those patients taking certain 
medications such as beta-blockers, cimetidine, or verapamil (Abernethy et al., 1983, Smith et 
al., 1985, Thomson et al., 1973). Despite these potential toxicities, there are few reports of 
significant complications related to topical anesthetic administration. An early survey of 
nearly 25,000 FFB only noted six patients with complications (respiratory arrest, seizures) 
related to airway anesthesia and only one patient with methemoglobinemia (Credle et al., 
1974). Additional concern was raised about volunteer FFB and the use of topical anesthesia 
was noted when a 19-year-old healthy volunteer died from lidocaine toxicity after 
undergoing a research FFB (Day et al., 1998).  
Although elevated methemoglobin levels are another potential concern with the use of 
higher lidocaine doses, there is scant information supporting this as a significant clinical 
issue. The 1974 bronchoscopy survey only noted symptoms related to methemoglobinemia 
in a single patient who received tetracaine (Credle et al., 1974). Recently, Karim et al. 
reported three patients who received topical lidocaine who developed clinical evidence of 
methemoglobinemia; one patient was undergoing FOB and was taking trimethoprim-
sulfamethoxazole (Karim et al., 2011). Most reported methemoglobinemia cases have been in 
association with benzocaine used in combination with lidocaine or as the sole topical 
anesthetic (Kern et al., 2000; Kucshner et al., 2000; O’Donohue & Moss, 1980; Rodriguez et 
al., 1994).  
6. Bronchoscopy in the ICU 
The 2001 BTS guidelines comment specifically on the differences for FFB performed in the 
intensive care unit (ICU) (BTS, 2001). There are a significant range of diagnostic 
(endobronchial cultures, lung collapse, hemoptysis, acute inhalation injury) and therapeutic 
(excess secretions, treatment of hemoptysis, foreign body removal) indications reported in 
the ICU setting (Anzueto et al., 1992; Shennib & Baislam, 1996). Intensive care units should 
be able to provide urgent and timely FFB to carry out these indications. From a safety 
perspective, these critically ill patients should be considered high risk for complications and 
absolutely require physiological monitoring during and after the procedure. In ventilated 
patients, the bronchoscopist can achieve higher levels of sedation and/or anesthesia to 
complete the diagnostic or therapeutic requirements for FFB. However, the bronchoscope 
must be able to pass easily through the endotracheal tube and the technique must allow 
adequate ventilation and oxygenation throughout (BTS, 2001). Hertz et al. demonstrated 
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that bronchoalveolar lavage could be performed successfully in ventilated patients without 
complications by using specific bronchoscopy techniques and proper ventilator 
management (Hertz et al., 1991) 
7. Conclusion 
Flexible fiberoptic bronchoscopy is a very important and useful tool for the pulmonologist 
to diagnose and treat various pulmonary disorders. Overall, it is a very safe procedure with 
low complication rates reported. There are several published guidelines to provide general 
guidance on the conduct of FFB. With proper preparation of the patient and close 
monitoring of the patient’s condition, FFB can be performed with the desired outcome. An 
important component of the overall process is to ensure that the patient is both as safe and 
comfortable as possible. Choosing the proper agent and level of sedation along with 
adequate topical anesthesia can make the experience better for the patient and the 
bronchoscopist. This chapter has provided a broad delineation of the studies in the medical 
literature that address the role of monitoring, oxygen supplementation, intravenous 
sedation, and topical anesthesia. 
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